Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2013

Open Access 01-12-2013 | Research

Burden of peripheral arterial disease in Europe and the United States: a patient survey

Authors: Elizabeth Marrett, Marco daCosta DiBonaventura, Qiaoyi Zhang

Published in: Health and Quality of Life Outcomes | Issue 1/2013

Login to get access

Abstract

Background

The aim of the current study was to quantify the burden of peripheral arterial disease (PAD) with respect to health-related quality of life, work productivity and activity impairment, and healthcare resource utilization.

Methods

Data were obtained from the 2010 EU National Health and Wellness Survey (NHWS), which included participants from France, Germany, Italy, Spain, and the UK (5EU, N = 57,805) as well as the 2010 US NHWS (N = 75,000). The NHWS is an annual, cross-sectional, self-administered Internet survey which employs a stratified random sampling frame to match the age and gender characteristics of the NHWS sample with known population statistics. Participants who self-reported a diagnosis of PAD were compared with participants who did not self-report a diagnosis of PAD on health-related quality of life (mental and physical component summary scores and health utilities from the Short Form-12v2), work productivity and activity impairment (Work Productivity and Activity Impairment questionnaire), and healthcare resource use in terms of the number of physician visits, emergency room visits, and hospitalizations in the past six months through regression modeling adjusting for demographics and health characteristics.

Results

A total of 743 (1.29%) and 777 (1.04%) participants self-reported a diagnosis of PAD in the 5EU and US, respectively. After adjusting for demographics and health characteristics, patients with PAD reported worse health-related quality of life, as measured by health utilities (5EU: 0.66 vs. 0.70; US: 0.66 vs. 0.72; all p < .05), greater overall work impairment percentage (5EU: 38.27% vs. 27.48%; US: 23.89% vs. 14.26%) and greater healthcare resource use compared to participants without PAD (all p < .05).

Conclusions

These results suggest a significant burden for patients with PAD in both the 5 EU countries and the US with respect to both quality of life and economic outcomes. Improved management of these patients may have profound effects from both patient and societal perspectives.
Appendix
Available only for authorised users
Literature
1.
Olin JW, Sealove BA: Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc 2010, 85: 678–692. 10.4065/mcp.2010.0133PubMedCentralPubMedCrossRef
2.
Ouriel K: Peripheral arterial disease. Lancet 2001, 358: 1257–1264. 10.1016/S0140-6736(01)06351-6PubMedCrossRef
3.
Dawson DL, Hagino RT: Critical limb ischemia. Curr Treat Options Cardiovasc Med 2001, 3: 237–249. 10.1007/s11936-001-0042-5PubMedCrossRef
4.
Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I: The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord 2005, 5: 14. 10.1186/1471-2261-5-14PubMedCentralPubMedCrossRef
5.
Selvin E, Erlinger TP: Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 2004, 110: 738–743. 10.1161/01.CIR.0000137913.26087.F0PubMedCrossRef
6.
Ramos R, Quesada M, Solanas P, Subirana I, Sala J, Vila J, Masiá R, Cerezo C, Elosua R, Grau M, Cordón F, Juvinyà D, Fitó M, Isabel Covas M, Clarà A, Angel Muñoz M, Marrugat J, REGICOR Investigators: Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk. Eur J Vasc Endovasc Surg 2009, 38: 305–311. 10.1016/j.ejvs.2009.04.013PubMedCrossRef
7.
Alzamora MT, Forés R, Baena-Díez JM, Pera G, Toran P, Sorribes M, Vicheto M, Reina MD, Sancho A, Albaladejo C, Llussà J, PERART/ARTPER study group: The peripheral arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population. BMC Public Health 2010, 10: 38. 10.1186/1471-2458-10-38PubMedCentralPubMedCrossRef
8.
Pujia A, Gnasso A, Mancuso G, Spagnuolo M, Cosco C, Cortese C, Colonna A, Mattioli PL: Asymptomatic arteriopathy of the lower limbs. Prevalence and risk factors in a population of southern Italy [Italian]. Minerva Cardioangiol 1993, 41: 133–138.PubMed
9.
Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ: Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991, 20: 384–392. 10.1093/ije/20.2.384PubMedCrossRef
10.
Kruidenier LM, Nicolaï SP, Willigendael EM, de Bie RA, Prins MH, Teijink JA: Functional claudication distance: a reliable and valid measurement to assess functional limitation in patients with intermittent claudication. BMC Cardiovasc Disord 2009, 9: 9. 10.1186/1471-2261-9-9PubMedCentralPubMedCrossRef
11.
Izquierdo-Porrera AM, Gardner AW, Bradham DD, Montgomery PS, Sorkin JD, Powell CC, Katzel LI: Relationship between objective measures of peripheral arterial disease severity to self-reported quality of life in older adults with intermittent claudication. J Vasc Surg 2005, 41: 625–630. 10.1016/j.jvs.2005.01.012PubMedCrossRef
12.
Tretinyak AS, Lee ES, Kuskowski MM, Caldwell MP, Santilli SM: Revascularization and quality of life for patients with limb-threatening ischemia. Ann Vasc Surg 2001, 15: 84–88.PubMedCrossRef
13.
Leicht AS, Crowther RG, Muller R, Golledge J: The effects of including quality of life responses in models to predict walking performance of patients with intermittent claudication. Eur J Vasc Endovasc Surg 2011, 41: 511–517. 10.1016/j.ejvs.2010.12.018PubMedCrossRef
14.
Margolis J, Barron JJ, Grochulski WD: Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Manag Care Pharm 2005, 11: 727–734.PubMed
15.
Mahoney EM, Wang K, Keo HH, Duval S, Smolderen KG, Cohen DJ, Steg G, Bhatt DL, Hirsch AT, Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators: Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes 2010, 3: 642–651. 10.1161/CIRCOUTCOMES.109.930735PubMedCrossRef
16.
Smolderen KG, Wang K, de Pouvourville G, Brüggenjürgen B, Röther J, Zeymer U, Parhofer KG, Steg PG, Bhatt DL, Magnuson EA, REACH Registry Investigators: Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease. Eur J Vasc Endovasc Surg 2012, 43: 198–207. 10.1016/j.ejvs.2011.09.016PubMedCrossRef
17.
Aronow WS: Management of peripheral arterial disease. Cardiol Rev 2005, 13: 61–68. 10.1097/01.crd.0000126082.86717.12PubMedCrossRef
18.
Duggan MM, Woodson J, Scott TE, Ortega AN, Menzoian JO: Functional outcomes in limb salvage vascular surgery. Am J Surg 1994, 168: 188–191. 10.1016/S0002-9610(94)80065-0PubMedCrossRef
19.
Chetter IC, Spark JI, Scott DJ, Kent PJ, Berridge DC, Kester RC: Prospective analysis of quality of life in patients following infrainguinal reconstruction for chronic critical ischaemia. Br J Surg 1998, 85: 951–955. 10.1046/j.1365-2168.1998.00752.xPubMedCrossRef
20.
Bosch JL, van der Graaf Y, Hunink MG: Health-related quality of life after angioplasty and stent placement in patients with iliac artery occlusive disease: results of a randomized controlled clinical trial. Circulation 1999, 99: 3155–3160. 10.1161/01.CIR.99.24.3155PubMedCrossRef
21.
Tangelder MJ, McDonnel J, Van Busschbach JJ, Buskens E, Algra A, Lawson JA, Eikelboom BC: Quality of life after infrainguinal bypass grafting surgery. J Vasc Surg 1999, 29: 913–919. 10.1016/S0741-5214(99)70219-3PubMedCrossRef
22.
Bosch JL, Hunink MG: The relationship between descriptive and valuational quality-of-life measures in patients with intermittent claudication. Med Decis Making 1996, 16: 217–225. 10.1177/0272989X9601600305PubMedCrossRef
23.
de Vries SO, Kuipers WD, Hunink MG: Intermittent claudication: symptom severity versus health values. J Vasc Surg 1998, 27: 422–430. 10.1016/S0741-5214(98)70316-7PubMedCrossRef
24.
Annunziata K, Rak A, Del Buono H, DiBonaventura M, Krishnarajah G: Vaccination rates among the general adult population and high-risk groups in the United States. PLoS ONE 2012, 7: e50553. 10.1371/journal.pone.0050553PubMedCentralPubMedCrossRef
25.
DiBonaventura MD, Chandran A, Hsu MA, Bushmakin A: Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom. Int J Womens Health In press
26.
Ware JE, Kosinski M, Turner-Bowker DM, Gandek B: How to Score Version 2 of the SF-12® Health Survey (With a Supplement Documenting Version 1). Lincoln, RI: QualityMetric Incorporated; 2002.
27.
Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42: 851–859. 10.1097/01.mlr.0000135827.18610.0dPubMedCrossRef
28.
Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993, 4: 353–365. 10.2165/00019053-199304050-00006PubMedCrossRef
29.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40: 373–383. 10.1016/0021-9681(87)90171-8PubMedCrossRef
30.
Walters SJ, Brazier JE: What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003, 1: 4. 10.1186/1477-7525-1-4PubMedCentralPubMedCrossRef
Metadata
Title
Burden of peripheral arterial disease in Europe and the United States: a patient survey
Authors
Elizabeth Marrett
Marco daCosta DiBonaventura
Qiaoyi Zhang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2013
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-11-175

Other articles of this Issue 1/2013

Health and Quality of Life Outcomes 1/2013 Go to the issue

Research

Impact on quality of life in teachers after educational actions for prevention of voice disorders: a longitudinal study

Research

Gaining the PROMIS perspective from children with nephrotic syndrome: a Midwest pediatric nephrology consortium study

Research

Assessment of quality of life of the children and parents affected by inborn errors of metabolism with restricted diet: preliminary results of a cross-sectional study

Research

Psychometric properties of KIDSCREEN-27 among childhood cancer survivors and age matched peers: a Rasch analysis

Research

Cross-cultural adaptation, reliability and validity of the Spanish version of the upper limb functional index

Research

Minimal clinically important differences for the EQ-5D and QWB-SA in Post-traumatic Stress Disorder (PTSD): results from a Doubly Randomized Preference Trial (DRPT)